Jacobio Pharmaceuticals (HKG:1167) completed dosing of the first patient for the phase 1/2a of its clinical trial or its JAB-23E73 anti-cancer drug in China, according to a Monday filing with the Hong Kong Exxchange.
The drug is an inhibitor of the Ki-ras2 Kirsten rat sarcoma viral oncogene homolog or KRAS, which is seen in various tumor mutations, the filing said.
Shares rose 1% during Monday's afternoon trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。